Blackstone Inc Allakos Inc. Transaction History

Blackstone Inc

$22 Billion
Q1 2025

A detailed history of Blackstone Inc transactions in Allakos Inc. stock. As of the latest transaction made, Blackstone Inc holds 14,943 shares of ALLK stock, worth $4,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,943

Previous 14,943 -0.0%

Holding current value

$4,931

Previous $18,000 83.33%

% of portfolio

0.0%

Previous 0.0%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.02 - $3.23 $4.16 Million - $13.2 Million	-4,081,709 Reduced 99.64%	14,943 $18,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $5.55 $4.45 Million - $11.6 Million	2,090,594 Added 104.21%	4,096,652 $9.3 Million
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $2.89 Million - $4.22 Million	803,061 Added 66.76%	2,006,058 $8.75 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $5.11 Million - $9.83 Million	1,188,054 Added 7950.57%	1,202,997 $5.35 Million
Q3 2021 Nov 16, 2021	BUY	$76.53 - $110.43 $1.14 Million - $1.65 Million	14,943 New	14,943 $1.58 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

61.7M

Call Options Held

71.5K

Put Options Held

19.8K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $28M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blackstone Inc, based on Form 13F filings with the SEC.

News

Stay updated on Blackstone Inc with notifications on news.

Account